Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients

Table 4 Comparisons of intestinal mucosal barrier function between the two groups (${\overline{\text{x}}} \pm {\text{s}}$)

	Experimental group (n = 65)			Control group (n = 65)			t^#	P^# value	t^$	P^$ value
	Before treatment	After treatment	Difference between before and after treatment	Before treatment	After treatment	Difference between before and after treatment	t^#	P^# value	t^$	P^$ value
Serum D lactic acid (mmol·L⁻¹)	5.62 ± 0.39	4.01 ± 0.08*	1.61 ± 0.31	5.63 ± 0.38	4.61 ± 0.02*	5.25 ± 0.36	− 58.662	< 0.001	− 61.772	< 0.001
ET (Eu·mL⁻¹)	0.25 ± 0.03	0.13 ± 0.02*	0.12 ± 0.01	0.24 ± 0.05	0.19 ± 0.01*	0.05 ± 0.04	− 21.633	< 0.001	13.688	< 0.001
DA0 (U·L⁻¹)	8.01 ± 1.02	5.38 ± 0.32*	2.63 ± 0.70	7.99 ± 0.97	6.83 ± 0.65*	1.16 ± 0.32	− 16.136	< 0.001	15.398	< 0.001

ET, endotoxin; DA0, diamine oxidase
^*Compared with that of before treatment, P < 0.001
^#Comparisons between experimental group and control group after treatment
^$Comparisons of difference in the values before and after treatment between the two groups

ISSN: 1471-230X